Eculizumab 300mg/30ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Eculizumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Eculizumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Eculizumab on the MHRA register
Bekemv 300mg/30ml concentrate for solution for infusion vials
Epysqli 300mg/30ml concentrate for solution for infusion vials
Soliris 300mg/30ml concentrate for solution for infusion vials
WHO defined daily dose (DDD)
64 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(11)
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) (TA647)
Eculizumab for treating refractory myasthenia gravis (terminated appraisal) (TA636)
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · Randomised trials: 10 · 2004–2026
Showing the 50 most relevant studies, sorted by most relevant.
Sonoko Misawa, Satoshi Kuwabara, Yasunori Sato, et al.
The Lancet Neurology, 2018
- Japan
- Motor Activity
- Recovery of Function
R. D. Wright, Fariba Bannerman, Michael W. Beresford, et al.
BMC Nephrology, 2020
- Hemoglobinuria, Paroxysmal
- Lupus Erythematosus, Systemic
- Lupus Nephritis
Sanjay Kulkarni, Nancy C. Kirkiles-Smith, Yun Hua Deng, et al.
American Journal of Transplantation, 2016
- Chronic Disease
- Complement C5
- Glomerular Filtration Rate
William H. Marks, Nizam Mamode, Robert A. Montgomery, et al.
American Journal of Transplantation, 2019
- Desensitization, Immunologic
- Graft Rejection
- Graft Survival
John Rathbone, Eva Kaltenthaler, Anna Richards, et al.
BMJ Open, 2013
M. G. Gonzalez Suarez, C. Thongprayoon, M. Mao, et al.
Journal of Clinical Medicine, 2019
P. D. de Zwart, Thomas F Mueller, G. Spartà, et al.
Pediatric Nephrology (Berlin, Germany), 2023
Rui Zhang, Meng Zhou, J. Qi, et al.
Frontiers in Immunology, 2021
2026
Sinha A, Bindal T, Zotta F, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
270-375h
Mechanism
Eculizumab is a monoclonal antibody that targets complement protein C5, preventi…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100%
[L6919]…
Half-life
270-375h
[A2247]
Protein binding
Volume of distribution
5-8L
[L6919]
Metabolism
[A179908][A40006]
Elimination
[A40006]…
Clearance
0.26mL
[A179908]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Eculizumab was granted FDA approval on 16 March 2007.[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria.[L46262][L46267]
[L6916][A2246]
It is also indicated in EU to treat PNH in both adult and pediatric patients.
[L46866]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 680 interactions
[L6922]
In case of overdose, contact local poison control.
[L6922]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L6919]
This drug reaches a Cmax of 194±76µg/mL and Ctrough of 97±60µg/mL.
[L6919]
The AUC was calculated to be 24,467.6µg\*h/mL.
[A179908]
[A2247]
[L6919]
[A179908][A40006]
[A40006]
Most monoclonal antibodies are catabolized in lysosomes to amino acids.
[A40006]
[A179908]
In patients with rhematoid arthritis, there is an average clearance of 0.26mL/kg/h.
[A179908]
Proteins and enzymes this drug interacts with in the body
PMID:12878586 PMID:18204047 PMID:30643019 PMID:6554279
Activated downstream of classical, alternative, lectin and GZMK complement pathways PMID:12878586 PMID:18204047 PMID:30643019 PMID:6554279
ATC L04AJ01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Eculizumab
Additional database identifiers
Drugs Product Database (DPD)
20432
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1331
GenAtlas
C5
GeneCards
C5
GenBank Gene Database
M57729
GenBank Protein Database
179983
UniProt Accession
CO5_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q421617), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.